Miriam K. Laufer

Miriam K. Laufer

Auto-generated profile, based on publicly available information

Miriam K. Laufer

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2006 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MLMiriam K. Laufer
Miriam K. Laufer
PTPhillip C. Thesing
Phillip C. Thesing
NENicole D. Eddington
Nicole D. Eddington
RMRhoda Masonga
Rhoda Masonga
FDFraction K. Dzinjalamala
Fraction K. Dzinjalamala
CPChristopher V. Plowe
Christopher V. Plowe
In 1993, Malawi became the first country in Africa to replace chloroquine with the combination of sulfadoxine and pyrimethamine for the treatment of malaria. At that time, the clinical efficacy of chloroquine was less than 50%. The molecular marker of chloroquine-resistant falciparum malaria subsequently declined in prevalence and was undetectable by 2001, suggesting that chloroquine might once again be effective in Malawi.

24 July 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JWJenny A. Walldorf
Jenny A. Walldorf
LCLauren M. Cohee
Lauren M. Cohee
JCJenna E. Coalson
Jenna E. Coalson
ABAndy Bauleni
Andy Bauleni
KNKondwani Nkanaunena
Kondwani Nkanaunena
MLMiriam K. Laufer
Miriam K. Laufer
Malaria surveillance and interventions in endemic countries often target young children at highest risk of malaria morbidity and mortality. We aimed to determine whether school-age children and adults not captured in surveillance serve as a reservoir for malaria infection and may contribute to malaria transmission. Cross-sectional surveys were conducted in one rainy and one dry season in southern Malawi. Demographic and health information was collected for all household members. Blood samples were obtained for microscopic and PCR identification of Plasmodium falciparum. Among 5796 individuals aged greater than six months, PCR prevalence of malaria infection was 5%, 10%, and 20% in dry, and 9%, 15%, and 32% in rainy seasons in Blantyre, Thyolo, and Chikhwawa, respectively. Over 88% of those infected were asymptomatic. Participants aged 6–15 years were at higher risk of infection (OR=4.8; 95%CI, 4.0–5.8) and asymptomatic infection (OR=4.2; 95%CI, 2.7–6.6) than younger children in all settings. School-age children used bednets less frequently than other age groups. Compared to young children, school-age children were brought less often for treatment and more often to unreliable treatment sources. Conclusion: School-age children represent an underappreciated reservoir of malaria infection and have less exposure to antimalarial interventions. Malaria control and elimination strategies may need to expand to include this age group.

1 September 2010 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MLMiriam K. Laufer
Miriam K. Laufer
STShannon Takala‐Harrison
Shannon Takala‐Harrison
FDFraction K. Dzinjalamala
Fraction K. Dzinjalamala
OSO. Colin Stine
O. Colin Stine
TTTerrie E. Taylor
Terrie E. Taylor
CPChristopher V. Plowe
Christopher V. Plowe
The spread of drug-resistant Plasmodium falciparum malaria has been a major impediment to malaria control and threatens prospects for elimination. We

17 April 2015 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
STShannon Takala‐Harrison
Shannon Takala‐Harrison
MLMiriam K. Laufer
Miriam K. Laufer

9 April 2014 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
AFAnne E. P. Frosch
Anne E. P. Frosch
MLMiriam K. Laufer
Miriam K. Laufer
DMDon P. Mathanga
Don P. Mathanga
STShannon Takala-Harrison
Shannon Takala-Harrison
JSJacek Skarbinski
Jacek Skarbinski
CPChristopher V. Plowe
Christopher V. Plowe
Background. The return of chloroquine-sensitive Plasmodium falciparum to the limited area of Blantyre, Malawi, has been well demonstrated in several studies. Methods. To characterize chloroquine susceptibility over a wide geographic area, infants and children aged 6–59 months were selected using 2-stage cluster sampling in 8 Malawian districts. Pyrosequencing of the pfcrt gene codon 76 region was performed for children with asexual parasitemia. Results. Of 7145 children, 1150 had microscopic asexual parasitemia, and sequencing was performed in 685, of whom 1 had a chloroquine-resistant genotype. Conclusions. Systematic countrywide sampling demonstrates that the chloroquine pfcrt genotype has reached near-fixation, raising the possibility of reintroducing chloroquine for malaria prevention and treatment.

8 January 2020 in Genome Medicine
Verified
Journal Article
Open access
PDF file
KMKara A. Moser
Kara A. Moser
EDElliott F. Drábek
Elliott F. Drábek
ADAnkit Dwivedi
Ankit Dwivedi
ESEmily M. Stucke
Emily M. Stucke
JCJonathan Crabtree
Jonathan Crabtree
JSJoana C. Silva
Joana C. Silva
Background: Plasmodium falciparum(Pf) whole-organism sporozoite vaccines have been shown to provide significant protection against controlled human malaria infection (CHMI) in clinical trials. Initial CHMI studies showed significantly higher durable protection against homologous than heterologous strains, suggesting the presence of strain-specific vaccine-induced protection. However, interpretation of these results and understanding of their relevance to vaccine efficacy have been hampered by the lack of knowledge on genetic differences between vaccine and CHMI strains, and how these strains are related to parasites in malaria endemic regions.Methods: Whole genome sequencing using long-read (Pacific Biosciences) and short-read (Illumina) sequencing platforms was conducted to generate de novo genome assemblies for the vaccine strain, NF54, and for strains used in heterologous CHMI (7G8 from Brazil, NF166.C8 from Guinea, and NF135.C10 from Cambodia). The assemblies were used to characterize sequences in each strain relative to the reference 3D7 (a clone of NF54) genome. Strains were compared to each other and to a collection of clinical isolates (sequenced as part of this study or from public repositories) from South America, sub-Saharan Africa, and Southeast Asia.Results: While few variants were detected between 3D7 and NF54, we identified tens of thousands of variants between NF54 and the three heterologous strains. These variants include SNPs, indels, and small structural variants that fall in regulatory and immunologically important regions, including transcription factors (such as PfAP2-L and PfAP2-G) and pre-erythrocytic antigens that may be key for sporozoite vaccine-induced protection. Additionally, these variants directly contributed to diversity in immunologically important regions of the genomes as detected through in silico CD8+T cell epitope predictions. Of all heterologous strains, NF135.C10 had the highest number of unique predicted epitope sequences when compared to NF54. Comparison to global clinical isolates revealed that these four strains are representative of their geographic origin despite long-term culture adaptation; of note, NF135.C10 is from an admixed population, and not part of recently formed subpopulations resistant to artemisinin-based therapies present in the Greater Mekong Sub-region.Conclusions: These results will assist in the interpretation of vaccine efficacy of whole-organism vaccines against homologous and heterologous CHMI.